EPISODE · Jun 28, 2024 · 1 MIN
Evolus Evolysse Comparable to Restylane-L in Dermal Filler Study
from AI Automation Minute · host Dr. Teri Fisher
This episode covers Evolus, Inc.'s latest advancements with their submission of two new dermal fillers, Evolysse™ Lift and Evolysse™ Smooth, to the U.S. FDA. In a pivotal study, these products were tested against Restylane-L and showed promising results for treating nasolabial folds. Dr. Rui Avelar, Chief Medical Officer at Evolus, shares his optimism about the FDA approval process. The episode highlights the potential impact of these new treatments in the field of cosmetic dermatology. Stay connected with Dr. Teri Fisher and explore the latest in AI and automation for healthcare: 🎥 Watch on YouTube for in-depth AI tutorials: YouTube.com/@DrTeriFisher📲 Follow on Instagram for automation tips: @DrTeriFisher💡 Discover AI tools for your practice: DrTeriFisher.com🎙 Listen to the long-form podcast: Anti-Aging Insights 👉 Subscribe to AI Automation Minute for your daily dose of AI-powered efficiency, and share with colleagues who want to work smarter, not harder! #AIAutomationMinute #DrTeriFisher #HealthcareAI
Embed this episode
What this episode covers
This episode covers Evolus, Inc.'s latest advancements with their submission of two new dermal fillers, Evolysse™ Lift and Evolysse™ Smooth, to the U.S. FDA. In a pivotal study, these products were tested against Restylane-L and showed promising results for treating nasolabial folds. Dr. Rui Avelar, Chief Medical Officer at Evolus, shares his optimism about the FDA approval process. The episode highlights the potential impact of these new treatments in the field of cosmetic dermatology. Sta...
NOW PLAYING
Evolus Evolysse Comparable to Restylane-L in Dermal Filler Study
No transcript for this episode yet
Similar Episodes
No similar episodes found.